As we navigate these challenging times, Certara is providing the drug development community with recent and relevant information regarding COVID-19 and facilitating professional development with on-demand resources. If you have any questions or comments, please contact us by filling out the form below.

Scientific Resources


Optimizing COVIDÔÇÉ19 candidate therapeutics: Thinking Without Borders

Timing of antiviral treatment initiation is critical to reduce SARS-Cov-2 viral load
Read More

The COVID-19 Coronavirus May Travel in Aerosols
Read More


Tiger tests positive for coronavirus at Bronx Zoo, first known case in the world

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

The Ethics of Wearing (or Not Wearing) a Face Mask During the Coronavirus Pandemic

GSK bets $250M on Vir's antibody approach to treating coronavirus

Webinars

Webinar: FDA Approval of Oral Testosterone Replacement Enabled by Phoenix NLME & Trial Simulator

Regulatory Resources

EMA Offers Guidance on Conducting Trials During the COVID-19 Pandemic

FDA Guidance on Conduct of Clinical Trials of Medical Products During COVID-19 Pandemic

Call to pool research resources into large multi-centre, multi-arm clinical trials to generate sound evidence on COVID-19 treatments

Clinical Trials During COVID-19: Updates From FDA, MHRA and TGA


How Certara is Supporting Our Clients

Certara recognizes the impact COVID-19 is having on our daily personal and business lives. We continue to support our customers' discovery and drug development efforts during this time with scientific informatics, model and simulation, and regulatory software tools and platforms to inform, improve and accelerate the process of bringing therapies to patients.

Business Continuity and Support

We continue to commit to maintaining business continuity of our technology and support efforts. Support channels continue to be staffed globally, providing 24/5 coverage to ensure rapid and meaningful responsiveness. Our remote and dispersed development and implementation staff and infrastructure, and our proven processes, and practices allow us to continue to operate, be productive, and stay connected to our customers.

Additional Resources Available

In order to facilitate a productive work environment during this time, the following resources are available:

  • Certara will be offering a temporary Phoenix license key to anyone affected by working remotely. Email [email protected] for more information.
  • On-demand webinars covering scientific use cases using Certara software are also available to view at any time. Visit Certara/Scientific Resources to access.
  • To view Certara BaseCase, an interactive communication platform, educational resources click here.

Please do not hesitate to contact your Account Manager or [email protected] with any questions or concerns.

Supporting Drug Development for COVID-19

Frequently Asked Questions (FAQ)

Are Certara staff now working remotely? 

  • Yes, all of our employees are working remotely. As a global company with almost 40 offices, we are well set up with a robust IT infrastructure.

Are there any Certara offices that are open?

  • Our physical locations are currently not available for access by visitors. But we remain open for business, and we still working hard to deliver on our commitments to you, our clients.

What are Certara’s business continuity plans?

  • We have reliable safeguards and robust business continuity plans in place and in operation currently. If you need additional information, please contact your project lead or account manager.

What is Certara doing about COVID-19?

  • Our top priority is the safety, health, and wellness of our employees and customers. We are listening to them and creating flexible solutions to support them in this challenging time. Remote working resources, as well as employee assistance programs, are available worldwide.
  • We are also partnering with several organizations on developing therapies for COVID-19.

What resources are available from Certara for professional development?

.